Scott Raney, Redpoint Ventures managing director, joins CNBC's 'The Exchange' to discuss outlooks on the IPO pipeline.

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. Titan America - Brussels, 24 ...

Birkenstock stock is trying to break out past a buy point, but shares came under pressure Friday as peer Decker Brands plunged on earnings.

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Underwriters have a 30-day option to buy an additional 1.8 million shares. Beta Bionics also agreed to sell 1 million shares in a private placement to an existing investor at $17 per share. Beta ...

Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.